MicroRNA-454-3p inhibits cervical cancer cell invasion and migration by targeting c-Met Retraction in /10.3892/etm.2024.12467

Guo,Yan; Tao,Min; Jiang,Min

doi:10.3892/etm.2018.5714

MicroRNA-454-3p inhibits cervical cancer cell invasion and migration by targeting c-Met

Retraction in: /10.3892/etm.2024.12467

Authors:
- Yan Guo
- Min Tao
- Min Jiang
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China
Published online on: January 8, 2018 https://doi.org/10.3892/etm.2018.5714
Pages: 2301-2306
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increasing evidence has demonstrated that microRNAs (miRNAs) have a crucial role in the initiation and progression of tumors. The present study aimed to investigate the expression and the role of miRNA‑454‑3p in human cervical cancer. Human cervical cancer cells were transfected with miRNA‑454‑3p mimics or negative control miRNA. MTT, Transwell and wound healing assays were performed to investigate the effects of miRNA‑454‑3p overexpression on cell proliferation, invasion and migration, respectively. The results indicated that miRNA‑454‑3p was down‑regulated in human cervical cancer cell lines, while its ectopic overexpression significantly inhibited their proliferation, migration and invasion. Furthermore, a luciferase reporter assay confirmed that c‑met was a novel target of miRNA‑454‑3p in HeLa cells. In conclusion, the results of the present study suggested that miRNA‑454‑3p exhibits significant tumor‑suppressive effects in cervical cancer by targeting c‑met, and may be a potential means of treating cervical cancer.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Smith RA, Brooks D, Cokkinides V, Saslow D and Brawley OW: Cancer screening in the United States, 2013: A review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin. 63:88–105. 2013. View Article : Google Scholar : PubMed/NCBI
3	Ambros V: MicroRNA pathways in flies and worms: Growth, death, fat, stress, and timing. Cell. 113:673–676. 2003. View Article : Google Scholar : PubMed/NCBI
4	Miska EA: How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev. 15:563–568. 2005. View Article : Google Scholar : PubMed/NCBI
5	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
6	Wozniak M, Mielczarek A and Czyz M: miRNAs in Melanoma: Tumor suppressors and oncogenes with prognostic potential. Curr Med Chem. 23:3136–3153. 2016. View Article : Google Scholar : PubMed/NCBI
7	Tsai MM, Wang CS, Tsai CY, Huang HW, Chi HC, Lin YH, Lu PH and Lin KH: Potential diagnostic, prognostic and therapeutic targets of MicroRNAs in human gastric cancer. Int J Mol Sci. 17:E9452016. View Article : Google Scholar : PubMed/NCBI
8	Zhu DY, Li XN, Qi Y, Liu DL, Yang Y, Zhao J, Zhang CY, Wu K and Zhao S: miR-454 promotes the progression of human non-small cell lung cancer and directly targets PTEN. Biomed Pharmacother. 81:79–85. 2016. View Article : Google Scholar : PubMed/NCBI
9	Fang B, Zhu J, Wang Y, Geng F and Li G: miR-454 inhibited cell proliferation of human glioblastoma cells by suppressing PDK1 expression. Biomed Pharmacother. 75:148–152. 2015. View Article : Google Scholar : PubMed/NCBI
10	Yu L, Gong X, Sun L, Yao H, Lu B and Zhu L: miR-454 functions as an oncogene by inhibiting CHD5 in hepatocellular carcinoma. Oncotarget. 6:39225–39234. 2015. View Article : Google Scholar : PubMed/NCBI
11	Liu L, Nie J, Chen L, Dong G, Du X, Wu X, Tang Y and Han W: The oncogenic role of microRNA-130a/301a/454 in human colorectal cancer via targeting Smad4 expression. Plos One. 8:e555322013. View Article : Google Scholar : PubMed/NCBI
12	Zhou L, Qu YM, Zhao XM and Yue ZD: Involvement of miR-454 overexpression in the poor prognosis of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 20:825–829. 2016.PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Niu G, Li B, Sun J and Sun L: miR-454 is down-regulated in osteosarcomas and suppresses cell proliferation and invasion by directly targeting c-Met. Cell Prolif. 48:348–355. 2015. View Article : Google Scholar : PubMed/NCBI
15	Fuse N, Kuboki Y, Kuwata T, Nishina T, Kadowaki S, Shinozaki E, Machida N, Yuki S, Ooki A, Kajiura S, et al: Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. Gastric Cancer. 19:183–191. 2016. View Article : Google Scholar : PubMed/NCBI
16	Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, Del Grammastro M, Sciarrotta MG, Buttitta F, Incarbone M, Toschi L, et al: Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 27:1667–1674. 2009. View Article : Google Scholar : PubMed/NCBI
17	Li B, Yang XX, Wang D and Ji HK: MicroRNA-138 inhibits proliferation of cervical cancer cells by targeting c-Met. Eur Rev Med Pharmacol Sci. 20:1109–1114. 2016.PubMed/NCBI
18	Baykal C and Ayhan A, Al A, Yüce K and Ayhan A: Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas. Gynecol Oncol. 88:123–129. 2003. View Article : Google Scholar : PubMed/NCBI
19	Refaat T, Donnelly ED, Sachdev S, Parimi V, El Achy S, Dalal P, Farouk M, Berg N, Helenowski I, Gross JP, et al: c-Met overexpression in cervical cancer, a prognostic factor and a potential molecular therapeutic target. Am J Clin Oncol 2015. in press.
20	Organ SL and Tsao MS: An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 3(1 Suppl): S7–S19. 2011. View Article : Google Scholar : PubMed/NCBI